Product Overview
Retatrutide is an investigational triple agonist peptide targeting GLP-1, GIP, and glucagon receptors. Designed to enhance metabolic regulation and promote weight management.
Recommended starting dose and titration schedule should be determined by a healthcare provider. Always follow your healthcare provider's specific instructions.
Do not use if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Use with caution in patients with a history of pancreatitis.
Retatrutide may affect the absorption of oral medications due to delayed gastric emptying. Inform your healthcare provider of all current medications.
Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and dyspepsia.
Retatrutide should not be used during pregnancy or breastfeeding.
Store refrigerated at 36°F to 46°F (2°C to 8°C). Protect from light. Do not freeze.
Contact your healthcare provider for specific questions about Retatrutide therapy.
Frequently asked
questions
Our team of experts has the answers you're looking for.
Please contact our customer service team for assistance finding healthcare providers.
Osmolarity information is available on the Certificate of Analysis (COA).
We offer many compounds not listed. Please contact us for specific formulations.
All ingredients are sourced from FDA-registered facilities.
Ready to get started?
Connect with our team to learn more about our compounding solutions and how we can support your practice.
Contact Us